As of May 27
| +0.08 / +1.69%|
The 7 analysts offering 12-month price forecasts for Cardiome Pharma Corp have a median target of 9.50, with a high estimate of 13.75 and a low estimate of 5.20. The median estimate represents a +97.10% increase from the last price of 4.82.
The current consensus among 7 polled investment analysts is to Buy stock in Cardiome Pharma Corp. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.